Ali A Habib

Title(s)Health Sciences Professor, Neurology
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-6832
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis. Adv Ther. 2024 Oct 29. Smith AG, Wolfe GI, Habib AA, Qi CZ, Yang H, Du M, Chen X, Gelinas D, Brauer E, Phillips G, Saccà F. PMID: 39470879.
      View in: PubMed   Mentions:    Fields:    
    2. US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization. Drugs Real World Outcomes. 2024 Oct 29. Nowak RJ, Habib AA, Klink AJ, Muppidi S, Parthan A, Sader SC, Balanean A, Gajra A, Howard JF, ELEVATE Study Group. PMID: 39470958.
      View in: PubMed   Mentions:
    3. Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Eur J Neurol. 2024 Oct 07; e16490. Habib AA, Benatar M, Vu T, Meisel A, Attarian S, Katsuno M, Liao S, Beasley KN, Howard JF. PMID: 39373062.
      View in: PubMed   Mentions:    Fields:    
    4. Effect of a Novel Ergonomic Sheath on Dental Device-Related Muscle Work, Fatigue and Comfort-A Pilot Clinical Study. Dent J (Basel). 2024 Sep 21; 12(9). Dang S, Wink C, Yang SM, Lin K, Takesh T, Habib AA, Wilder-Smith P. PMID: 39329862; PMCID: PMC11431630.
      View in: PubMed   Mentions:
    5. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. Ther Adv Neurol Disord. 2024; 17:17562864241273036. Habib AA, Sacconi S, Antonini G, Cortés-Vicente E, Grosskreutz J, Mahuwala ZK, Mantegazza R, Pascuzzi RM, Utsugisawa K, Vissing J, Vu T, Wiendl H, Boehnlein M, Greve B, Woltering F, Bril V. PMID: 39297052; PMCID: PMC11409299.
      View in: PubMed   Mentions:
    6. Effect of a Novel Adaptive Handle Design on the Ergonomic Performance of Periodontal Curettes in Dental Hygienists with and without Musculoskeletal Disorders: A Pilot Clinical Study. Dent J (Basel). 2024 Aug 13; 12(8). Wink C, Yang SM, Habib AA, Lin K, Takesh T, Wilder-Smith P. PMID: 39195097; PMCID: PMC11352665.
      View in: PubMed   Mentions: 1  
    7. United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use. J Neurol. 2024 Sep; 271(9):6114-6126. Habib AA, Klink AJ, Muppidi S, Parthan A, Sader SC, Balanean A, Gajra A, Nowak RJ, Howard JF, ELEVATE Study Group. PMID: 39052039; PMCID: PMC11377470.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Clinical meaningfulness and psychometric robustness of the MG Symptoms PRO scales in clinical trials in adults with myasthenia gravis. Front Neurol. 2024; 15:1368525. Regnault A, Habib AA, Creel K, Kaminski HJ, Morel T. PMID: 38978809; PMCID: PMC11229520.
      View in: PubMed   Mentions:
    9. Would glucocorticoids be approved for clinical use if discovered today? Muscle Nerve. 2024 Jul; 70(1):9-11. Habib AA, Narayanaswami P. PMID: 38720486.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. A Multidisciplinary Assessment of ChatGPT's Knowledge of Amyloidosis: Observational Study. JMIR Cardio. 2024 Apr 19; 8:e53421. King RC, Samaan JS, Yeo YH, Peng Y, Kunkel DC, Habib AA, Ghashghaei R. PMID: 38640472; PMCID: PMC11069089.
      View in: PubMed   Mentions: 2  
    11. Hospitalizations and Mortality From Myasthenia Gravis: Trends From 2 US National Datasets Neurology. 2024 01 23; 102(2):e207863. Habib AA, Sacks N, Cool C, Durgapal S, Dennen S, Everson K, Hughes T, Hernandez J, Phillips G. PMID: 38165317.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    12. A Novel Ergonomic Curette Design Reduces Dental Prophylaxis-Induced Muscle Work and Fatigue. Dent J (Basel). 2023 Nov 28; 11(12). Lin K, Wink C, Dolan B, Osann K, Habib AA, Gehrig J, Wilder-Smith P. PMID: 38132410; PMCID: PMC10742551.
      View in: PubMed   Mentions: 2  
    13. Correction to: Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO. Neurol Ther. 2023 Oct; 12(5):1591-1592. Regnault A, Morel T, de la Loge C, Mazerolle F, Kaminski HJ, Habib AA. PMID: 37368226; PMCID: PMC10444721.
      View in: PubMed   Mentions: 1  
    14. Advancements in targeted therapies for generalized acetylcholine receptor antibody positive myasthenia gravis: Beginnings of a paradigm shift. Eur J Neurol. 2023 12; 30(12):3644-3645. Habib AA, Schneider-Gold C. PMID: 37578121.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. Muscle Nerve. 2023 Nov; 68(5):762-766. Katyal N, Halldorsdottir K, Govindarajan R, Shieh P, Muley S, Reyes P, Leung KK, Mullen J, Milani-Nejad S, Korb M, Goyal NA, Mozaffar T, Goyal N, Habib AA, Muppidi S. PMID: 37695277.
      View in: PubMed   Mentions: 6     Fields:    
    16. Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs. Front Public Health. 2023; 11:1147489. Hughes T, Anderson AEL, Habib AA, Perez K, Bergin C, Suchotliff S, Zvosec C, McDaniel D, Sato M, Whangbo A, Phillips G. PMID: 37275500; PMCID: PMC10235801.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO. Neurol Ther. 2023 Oct; 12(5):1573-1590. Regnault A, Morel T, de la Loge C, Mazerolle F, Kaminski HJ, Habib AA. PMID: 37166675; PMCID: PMC10444722.
      View in: PubMed   Mentions: 6  
    18. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023 05; 22(5):383-394. Bril V, Druzdz A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ, MG0003 study team. PMID: 37059507.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    19. Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials. Neurology. 2023 09 05; 101(10):442-451. Guptill JT, Benatar M, Granit V, Habib AA, Howard JF, Barnett-Tapia C, Nowak RJ, Lee I, Ruzhansky K, Dimachkie MM, Cutter GR, Kaminski HJ, for MGNet Clinical Trial Outcome Measure Working Group. PMID: 37076302; PMCID: PMC10491448.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    20. Primary lateral sclerosis natural history study - planning, designing, and early enrollment. Amyotroph Lateral Scler Frontotemporal Degener. 2023 08; 24(5-6):394-404. Mitsumoto H, Jang G, Lee I, Simmons Z, Sherman AV, Heitzman D, Sorenson E, Cheung K, Andrews J, Harms M, Shneider NA, Santella R, Paganoni S, Ajroud-Driss S, Fernandes JAM, Burke KM, Gwathmey K, Habib AA, Maragakis NJ, Walk D, Fournier C, Heiman-Patterson T, Wymer J, Diaz F, Scelsa SN, Elman L, Genge A, Goutman SA, Hayat G, Jawdat O, Johnston WS, Joyce NC, Kasarskis EJ, Kisanuki YY, Lomen-Hoerth C, Pulley MT, Shah JS, Shoesmith C, Zinman L, PLS Natural History Study Group.. PMID: 36576200.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    21. Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease. Neurology. 2022 Jun 06; 98(23):e2356-e2367. Thomas FP, Brannagan TH, Butterfield RJ, Desai U, Habib AA, Herrmann DN, Eichinger KJ, Johnson NE, Karam C, Pestronk A, Quinn C, Shy ME, Statland JM, Subramony SH, Walk D, Stevens-Favorite K, Miller B, Leneus A, Fowler M, van de Rijn M, Attie KM. PMID: 35545446; PMCID: PMC9202530.
      View in: PubMed   Mentions: 10     Fields:    
    22. Patient preference for virtual versus in-person visits in neuromuscular clinical practice. Muscle Nerve. 2022 08; 66(2):142-147. Hafeez K, Kushlaf H, Al-Sultani H, Joseph AC, Zaeem Z, Siddiqi Z, Laboy S, Pulley M, Habib AA, Robbins NM, Zadeh S, Hafeez MU, Hussain Y, Melendez-Zaidi A, Kassardjian C, Johnson K, Leonhard H, Biliciler S, Patino Murillas JE, Shaibani AI. PMID: 35596667; PMCID: PMC9540760.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    23. Intron mutations and early transcription termination in Duchenne and Becker muscular dystrophy. Hum Mutat. 2022 04; 43(4):511-528. Waldrop MA, Moore SA, Mathews KD, Darbro BW, Medne L, Finkel R, Connolly AM, Crawford TO, Drachman D, Wein N, Habib AA, Krzesniak-Swinarska MA, Zaidman CM, Collins JJ, Jokela M, Udd B, Day JW, Ortiz-Guerrero G, Statland J, Butterfield RJ, Dunn DM, Weiss RB, Flanigan KM. PMID: 35165973; PMCID: PMC9901284.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    24. Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study. Neurotherapeutics. 2021 Jul; 18(3):2130. Rudnicki SA, Andrews JA, Duong T, Cockroft BM, Malik FI, Meng L, Wei J, Wolff AA, Genge A, Johnson NE, Tesi-Rocha C, Connolly AM, Darras BT, Felice K, Finkel RS, Shieh PB, Mah JK, Statland J, Campbell C, Habib AA, Kuntz NL, Oskoui M, Day JW. PMID: 34731415; PMCID: PMC8609058.
      View in: PubMed   Mentions: 1     Fields:    
    25. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study. Neurotherapeutics. 2021 04; 18(2):1127-1136. Rudnicki SA, Andrews JA, Duong T, Cockroft BM, Malik FI, Meng L, Wei J, Wolff AA, Genge A, Johnson NE, Tesi-Rocha C, Connolly AM, Darras BT, Felice K, Shieh PB, Mah JK, Statland J, Campbell C, Habib AA, Kuntz NL, Oskoui M, Day JW, Finkel RS. PMID: 33624184; PMCID: PMC8423982.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    26. Attitudes Toward Noninterventional Observational Studies in US and Australian Patients With Sporadic Inclusion Body Myositis. J Clin Neuromuscul Dis. 2020 Jun; 21(4):246-247. Mathew V, Wencel M, Habib AA, Goyal NA, Needham M, Mozaffar T. PMID: 32453104.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. Update on immune-mediated therapies for myasthenia gravis. Muscle Nerve. 2020 11; 62(5):579-592. Habib AA, Ahmadi Jazi G, Mozaffar T. PMID: 32462710.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    28. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol. 2020 05 01; 77(5):582-592. Howard JF, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ, Zilucoplan MG Study Group, Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib AA, Mathew V, Mozaffar T, Hinton JL, Hewitt W, Barnett D, Sullivan P, Ho D, Howard JF, Traub RE, Chopra M, Kaminski HJ, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon LM, Lisak RP, Bernitsas E, Jia K, Malik R, Lewis-Collins TD, Nicolle M, Nowak RJ, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe GI, Silvestri N, Patrick K, Zakalik K, Duda PW, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M. PMID: 32065623; PMCID: PMC7042797.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    29. Therapeutic strategies for diabetic neuropathy. Curr Neurol Neurosci Rep. 2010 Mar; 10(2):92-100. Habib AA, Brannagan TH. PMID: 20425233.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    30. The neuropathology of leprosy. Arch Neurol. 2002 Jan; 59(1):138-40. Habib AA, Mozaffar T. PMID: 11790242.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Ali's Networks
    Concepts (72)
    Derived automatically from this person's publications.
    _
    Co-Authors (9)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _